| Mallinckrodt Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20130183236 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS - The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject. | 07-18-2013 |
| 20120059167 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA BETA-UNSATURATED COMPOUNDS - The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of α,β-unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound. (A) | 03-08-2012 |
| 20120035472 | Medical Fluid Delivery System with Reusable RFID Fixture - Systems and methods are presented for delivering medical fluids to a patient. A data storage device ( | 02-09-2012 |
| 20110288033 | Disulfide Compounds for Phototherapy - The invention relates generally to optical agents for biomedical applications, including phototherapy. Provided are disulfide compounds having an acyclic S—S bond with at least one aromatic and/or heterocyclic aromatic group providing phototherapeutic agents, including Type 1 phototherapeutic agents. Optical agents of the invention enable a versatile phototherapy platform for treatment of a range of pathological conditions, including the treatment of cancers, stensosis and inflammation. The invention further provides preparations and formulations comprising the disulfide optical agents and related methods of making and using disulfide optical agents in an in vivo or ex vivo biomedical procedure. | 11-24-2011 |
| 20110272428 | METHOD AND APPARATUS FOR DISPOSAL OF A PHARMACEUTICAL PRODUCT BLISTER CARD - A pharmaceutical product supply including primary packaging (e.g., a blister card) having a plurality of receptacles and pharmaceutical product (e.g., one or more pills, capsules, etc.) enclosed within at least one of the receptacles. Heating the pharmaceutical product supply to at least an activation temperature of a heat-activated encapsulation material associated with the supply may encapsulate the pharmaceutical product to reduce the likelihood that the pharmaceutical product can thereafter be administered, and thereby facilitates disposal of the pharmaceutical product. In one embodiment, a tray of a primary packaging is constructed of the heat-activated encapsulation material. In another embodiment, primary packaging may be disposed within a cavity of secondary packaging (e.g., carton), and the heat-activated encapsulation material may be in the form of a layer that is also located within the cavity. | 11-10-2011 |
| 20110272426 | PEN-TYPE PHARMACEUTICAL PRODUCT DISPENSER - Pharmaceutical product dispensers (e.g., in the shape of a common ink pen) are operable to indicate information regarding a dosing schedule of a pharmaceutical product dispensable from the dispenser. Embodiments of the dispensers may include a plurality of dosing segments, each corresponding to a different dose of the pharmaceutical product. Actuation of an actuator may result in interaction between the actuator and the pharmaceutical product storage area such that a dose of pharmaceutical product contained in the pharmaceutical product storage area is dispensed, along with a corresponding advancement of the plurality of dosing segments. The dispenser may also include one or more locks to prevent unauthorized access to the pharmaceutical product (e.g., by a child or the like). Furthermore, the pharmaceutical product dispenser may include a disabling mechanism to permanently disable actuation of the actuator of the dispenser. | 11-10-2011 |
| 20110272323 | SEALABLE SECONDARY PACKAGING FOR PHARMACEUTICAL PRODUCT BLISTER PACK - A pharmaceutical product supply is disclosed in the form of a container, a pharmaceutical product receiver, pharmaceutical product, an adhesive, and at least one release liner. The pharmaceutical product receiver includes a plurality of receptacles for pharmaceutical product. The container is initially disposed in a first configuration where all of the pharmaceutical product receiver receptacles may be accessible. The container is thereafter disposable in a second configuration where no covering for any of the pharmaceutical product receiver receptacles is accessible through any openable access incorporated by the container. One or more release liners may be moved to expose adhesive for disposing and retaining the container in its second configuration. The noted second configuration of the container facilitates disposal of the pharmaceutical product supply (e.g., now being in a form that should reduce the potential for gaining access to any remaining pharmaceutical product still enclosed within the pharmaceutical product receiver). | 11-10-2011 |
| 20110272297 | PHARMACEUTICAL PRODUCT CONTAINER WITH PERMANENT LOCKING MECHANISM - Various embodiments of pharmaceutical product containers are disclosed. Each pharmaceutical product container includes a cap, a container body, and a locking mechanism. The locking mechanism is disposable from a locked state to an unlocked state at least when the cap is in a closed position relative to the container body (e.g., to define an enclosed space for pharmaceutical product). Once in the locked state and with the cap being in a closed position, the locking mechanism is unable to return to its unlocked state. Pharmaceutical product enclosed within the container with the locking mechanism being in its locked state may then be disposed of in any appropriate manner (e.g., discarded in the trash). | 11-10-2011 |
| 20110269964 | N-Alkylation of Opiates - The present invention provides an efficient process for preparing N-alkylated opiates. In particular, processes are provided for using a chloride-containing alkylating agent and a bromide or iodide salt to alkylate the corresponding nor-opiate. | 11-03-2011 |
| 20110269963 | Preparation of Saturated Ketone Morphinan Compounds Having Low Metal Content - The present invention provides processes for the preparation of saturated ketone morphinan compounds from a morphinan comprising an allyl alcohol ring moiety, wherein the final product has a low metal content. In particular, the invention provides processes that utilize isomerization reactions catalyzed by transition metal catalysts and the subsequent removal of the transition metal using metal scavengers. | 11-03-2011 |
| 20110253572 | DISPOSABLE TRANSDERMAL PATCH PACKAGING - A transdermal patch container ( | 10-20-2011 |
| 20110227734 | PHARMACEUTICAL PRODUCT CONTAINER WITH MOTION SENSOR AND ALARM - Systems and methods for monitoring a container ( | 09-22-2011 |
| 20110226817 | SYSTEMS AND METHODS FOR MANGING USE OF A MEDICAMENT - Systems and methods for managing use of a pharmaceutical product ( | 09-22-2011 |
| 20110225936 | APPARATUSES AND METHODS FOR STORING PHARMACEUTICAL PRODUCT - A container ( | 09-22-2011 |
| 20110216627 | SYSTEMS AND METHODS FOR TIMING DOSAGE PERIODS - Systems and methods for tracking dosage periods are disclosed. The systems and methods may include setting a timer ( | 09-08-2011 |
| 20110215267 | Radiation-Shielding Assemblies And Methods of Using The Same - In one characterization, the present invention relates to a radiation-shielding assembly for holding a container having a radioactive material disposed therein. The assembly may, at least in one regard, be referred to as an elution shield and/or a dispensing shield. The assembly includes a body at least partially defining a cavity. There is at least one opening through the body into the cavity. The assembly may include a cap that at least generally hinders escape of radiation from the assembly through the opening. The cap may be releasably attached to the body in one orientation and may establish non-attached engagement with the body in another orientation. The assembly may include an adjustable spacer system for adapting the assembly for use with containers having different heights. | 09-08-2011 |
| 20110215266 | Radiation-Shielding Assemblies And Methods of Using The Same - In one characterization, the present invention relates to a radiation-shielding assembly for holding a container having a radioactive material disposed therein. The assembly may, at least in one regard, be referred to as an elution shield and/or a dispensing shield. The assembly includes a body at least partially defining a cavity. There is at least one opening through the body into the cavity. The assembly may include a cap that at least generally hinders escape of radiation from the assembly through the opening. The cap may be releasably attached to the body in one orientation and may establish non-attached engagement with the body in another orientation. The assembly may include an adjustable spacer system for adapting the assembly for use with containers having different heights. | 09-08-2011 |
| 20110215265 | Radiation-Shielding Assemblies And Methods of Using The Same - In one characterization, the present invention relates to a radiation-shielding assembly for holding a container having a radioactive material disposed therein. The assembly may, at least in one regard, be referred to as an elution shield and/or a dispensing shield. The assembly includes a body at least partially defining a cavity. There is at least one opening through the body into the cavity. The assembly may include a cap that at least generally hinders escape of radiation from the assembly through the opening. The cap may be releasably attached to the body in one orientation and may establish non-attached engagement with the body in another orientation. The assembly may include an adjustable spacer system for adapting the assembly for use with containers having different heights. | 09-08-2011 |
| 20110215264 | Radiation-Shielding Assemblies And Methods of Using The Same - In one characterization, the present invention relates to a radiation-shielding assembly for holding a container having a radioactive material disposed therein. The assembly may, at least in one regard, be referred to as an elution shield and/or a dispensing shield. The assembly includes a body at least partially defining a cavity. There is at least one opening through the body into the cavity. The assembly may include a cap that at least generally hinders escape of radiation from the assembly through the opening. The cap may be releasably attached to the body in one orientation and may establish non-attached engagement with the body in another orientation. The assembly may include an adjustable spacer system for adapting the assembly for use with containers having different heights. | 09-08-2011 |
| 20110215021 | CONTAINER AND METHOD FOR FACILITATING DISPOSAL OF UNUSED PHARMACEUTICAL PRODUCT - Containers and methods for disposing unused pharmaceutical product are disclosed. Each container ( | 09-08-2011 |
| 20110144487 | Power Injector with Syringe Communication Logic - A power injector ( | 06-16-2011 |
| 20110144486 | Power Injector with Syringe Communication Logic - A power injector ( | 06-16-2011 |
| 20110136845 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof - The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain. | 06-09-2011 |
| 20110077222 | Sustained-Release Opiate and Opiate Derivative Compositions - The present invention provides sustained-release opiate compositions. In particular, the present invention provides sustained-release opiate compositions that include an opiate attached to a blood albumin binder. The present invention also relates to methods of administering an opiate with a sustained release pharmacokinetic profile. | 03-31-2011 |
| 20110071300 | One-Pot Preparation of Hexahydroisoquinolines from Dihydroisoquinolines - The present invention provides an efficient process for the preparation of hexahydroisoquinolines from dihydroisoquinolines. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines. | 03-24-2011 |
| 20110071299 | One-Pot Preparation of Hexahydroisoquinolines from Amides - The present invention provides an efficient process for the preparation of hexahydroisoquinolines from amides. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines. | 03-24-2011 |
| 20110071297 | Methods for Producing Hydrocodone, Hydromorphone or a Derivative Thereof - The present disclosure generally relates to methods for producing opioid derivatives. More particularly, the present disclosure relates to the preparation of hydromorphone, hydrocodone, or a derivative thereof, by means of a non-catalytic hydrogenation reaction of thebaine, oripavine or a derivative thereof, respectively, using a hydrazide reagent, followed by hydrolysis of the hydrogenated intermediate at a low temperature and for a short period of time. Additionally, the present disclosure relates to a composition comprising the desired hydromorphone, hydrocodone, or a derivative thereof, in combination with a 6-beta compound that is structurally related thereto. | 03-24-2011 |
| 20110071296 | Preparation of 10-Keto Morphinans by Benzylic Oxidation - The present invention provides processes for the preparation of 10-keto and/or 10-hydroxy morphinans. In particular, the invention provides to processes for preparing a 10-keto morphinan by chromium-catalyzed benzylic oxidation of a morphinan with a periodic acid. | 03-24-2011 |
| 20110071016 | Heterogeneous Ruthenium Metal Catalyst for the Production of Hydrocodone, Hydromorphone or a Derivative Thereof - The present disclosure generally relates to catalytic methods for producing opioid derivatives. More particularly, the present disclosure relates to the preparation of hydrocodone, hydromorphone, or a derivative thereof, by means of a conversion or an isomerization of codeine, morphine, or a derivative thereof, respectively, using a heterogeneous ruthenium metal catalyst. | 03-24-2011 |
| 20110067703 | MEDICAL DEVICE WITH ANTIMICROBIAL LAYER - A medical device includes a conduit for a fluid. The conduit has a wall formed of a hydrophobic polymer with a hydrophilic polymer layer extruded over it, and an antimicrobial substantially dispersed within the hydrophilic polymer. The antimicrobial compound may be a predetermined amount of phosphorus-based glass having a predetermined quantity of a metal such as silver substantially dispersed therein. The medical device may be an endotracheal tube made by providing a hydrophobic polymer, a hydrophilic polymer and an antimicrobial compound, forming the hydrophobic polymer, the hydrophilic polymer and the antimicrobial compound into a conduit, and forming a cuff on an end of the conduit. | 03-24-2011 |
| 20110015398 | 3-Oxy-Hydromorphone Derivatives - The present invention provides 3-oxy-hydromorphone derivatives, and in particular, 3-ester, 3-carbonate, and 3-sulfonate derivatives of hydromorphone. | 01-20-2011 |
| 20110015219 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof - The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as a method for identifying (+)-morphinans that may be therapeutically effective by determining whether the (+)-morphinan inhibits the activation of TLR9. Also provided are methods of using the (+)-morphinans comprising TLR9 antagonist activity to treat conditions such as traumatic pain, neuropathic pain, inflammatory disorders, acetaminophen toxicity, autoimmune disorders, neurodegenerative disorders, and cancer. | 01-20-2011 |
| 20110009633 | Method for the Enrichment of Buprenorphine using Chromatographic Techniques - The present invention provides processes for the enrichment of buprenorphine in a product. In particular, the present invention provides processes for the enrichment of buprenorphine in a product using chromatographic techniques. | 01-13-2011 |
| 20100317861 | Remove Amination of 6-Keto Normorphinans by Catalytic Hydrogen Transfer - The present invention provides processes for the stereoselective synthesis of 6-alpha-amino morphinans. In particular, the invention provides processes for the reductive amination of 6-keto normorphinans by catalytic transfer hydrogenation. | 12-16-2010 |
| 20100317683 | Preparation of 6-Alpha-Amino N-Substituted Morphinans by Catalytic Hydrogen Transfer - The present invention provides processes for the stereoselective synthesis of 6-alpha-amino N-substituted morphinans. In particular, the invention provides processes for the reductive amination of 6-keto N-substituted morphinans by catalytic hydrogen transfer. | 12-16-2010 |
| 20100316721 | Granular Sustained Release Preparation and Production Thereof - There is disclosed a novel sustained release granular resin-pharmaceutical composition comprising an ion exchange resin complexed with a pharmaceutical material wherein said complex is embedded into and on the surface of a diffusion barrier material. There is also disclosed a novel process for preparing the granulated complex wherein an aqueous granulating vehicle is employed to form the complex and the granulated product, thereby avoiding the use of coatings and large amounts of organic solvents in the process. | 12-16-2010 |
| 20100311946 | Solid Phase Peptide for the Production of Goserelin - The present invention provides a process for the production of goserelin. In particular, the process of the invention allows the use of side chain protecting groups during synthesis of the peptide, and the addition of the azaglycine moiety of the peptide. | 12-09-2010 |
| 20100305688 | Medical Devices for Localized Drug Delivery - In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent. | 12-02-2010 |
| 20100303882 | Medical Devices for Localized Drug Delivery - In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent. | 12-02-2010 |
| 20100286359 | Solid Support for FMOC-Solid Phase Synthesis of Peptide Acids - The present invention provides a solid support for Fmoc-solid phase synthesis of peptides. In particular, the solid supports of the invention may be utilized to produce peptide acids. | 11-11-2010 |
| 20100280232 | MULTICOMPONENT ASSEMBLIES HAVING ENHANCED BINDING PROPERTIES FOR DIAGNOSIS AND THERAPY - An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patient who is then diagnosed or treated using the effector molecule. | 11-04-2010 |
| 20100280177 | MULTICOMPONENT ASSEMBLIES HAVING ENHANCED BINDING PROPERTIES FOR DIAGNOSIS AND THERAPY - An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule. | 11-04-2010 |
| 20100274128 | Fluid Driven Medical Injectors - Some injectors of the invention may include a fluid drive responsive to pressure of a working fluid (e.g., liquid, pneumatic, or both) to impart a sequence of forces to drive a delivery device (e.g., a syringe) to deliver a medical fluid (e.g., a contrast agent, a radiopharmaceutical, a drug, or a combination thereof). Some injectors may include a multimedia tube configured to pass a working fluid (e.g., air) and a light signal (e.g., infrared). Some injectors may include a peristaltic drive responsive to pressure of a working fluid. | 10-28-2010 |
| 20100274127 | Fluid Driven Medical Injectors - Some injectors of the invention may include a fluid drive responsive to pressure of a working fluid (e.g., liquid, pneumatic, or both) to impart a sequence of forces to drive a delivery device (e.g., a syringe) to deliver a medical fluid (e.g., a contrast agent, a radiopharmaceutical, a drug, or a combination thereof). Some injectors may include a multimedia tube configured to pass a working fluid (e.g., air) and a light signal (e.g., infrared). Some injectors may include a peristaltic drive responsive to pressure of a working fluid. | 10-28-2010 |
| 20100274126 | Fluid Driven Medical Injectors - Some injectors of the invention may include a fluid drive responsive to pressure of a working fluid (e.g., liquid, pneumatic, or both) to impart a sequence of forces to drive a delivery device (e.g., a syringe) to deliver a medical fluid (e.g., a contrast agent, a radiopharmaceutical, a drug, or a combination thereof). Some injectors may include a multimedia tube configured to pass a working fluid (e.g., air) and a light signal (e.g., infrared). Some injectors may include a peristaltic drive responsive to pressure of a working fluid. | 10-28-2010 |
| 20100262002 | Syringe Identification System - A syringe ( | 10-14-2010 |
| 20100261907 | Preparation of Saturated Ketone Morphinan Compounds - The present invention provides processes for the preparation of saturated ketone morphinan compounds. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an inorganic salt of a late transition metal. | 10-14-2010 |
| 20100261906 | Preparation of 6-Keto, 3-Alkoxy Morphinans - The present invention provides processes for the preparation of saturated 6-keto, 3-alkoxy morphinans from unsaturated 6-hydroxy, 3-hydroxy morphinans, In particular, the invention provides processes that utilize catalytic isomerization and alkylation reactions for the preparation of saturated 6-keto, 3-alkoxy morphinans. | 10-14-2010 |
| 20100261905 | Ruthenium Catalysts for the Production of Hydrocodone, Hydromorphone or a Derivative Thereof - The present disclosure generally relates to catalytic methods for producing opioid derivatives. More particularly, the present disclosure relates to the preparation of hydrocodone, hydromorphone, or a derivative thereof, by means of an isomerization of codeine, morphine, or a derivative thereof, respectively, using a ruthenium catalyst. | 10-14-2010 |
| 20100261904 | Preparation of Saturated Ketone Morphinan Compounds by Catalytic Isomerization - The present invention provides processes for the preparation of saturated ketone morphinan compounds by catalytic isomerization. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an allyl-transition metal catalyst. | 10-14-2010 |
| 20100216998 | Facile "One Pot' Process for Apomorphine From Codeine - An improved method for producing apomorphine and derivatives thereof is provided. The method is a convenient ‘one-pot’ process, comprising the conversion of codeine into apomorphine without isolating the apocodeine intermediate. Use of water reactive scavengers, reagents that will react irreversibly with water, decreases side product formation and allows the use of milder reaction conditions. This one-pot synthesis of apomorphine from codeine provides a faster reaction with improved yields at temperatures lower as compared to conventional methods. The lower operating temperatures and less volatile reactants make the method particularly useful for large-scale manufacturing. | 08-26-2010 |
| 20100216997 | (+)-Morphinanium N-Oxides and Processes for their Production - The present invention provides (+)-morphinanium N-oxide compounds or pharmaceutically acceptable salts thereof. The invention also provides processes for producing (+)-morphinanium N-oxides or pharmaceutically acceptable salts thereof from the corresponding tertiary N-substituted (+)-morphinan compound or pharmaceutically acceptable salt thereof. | 08-26-2010 |
| 20100216996 | (+)-Morphinanium Quaternary Salts and Processes for their Production - The present invention provides (+)-morphinanium quaternary salts. The invention also provides processes for producing (+)-morphinanium quaternary salts from tertiary N-substituted (+)-morphinan compounds. | 08-26-2010 |
| 20100216995 | (+)-6-Hydroxy-Morphinan or (+)-6-Amino-Morphinan Derivatives - The present invention provides (+)-morphinanium compounds comprising substituted 6-hydroxy or 6-amine groups. The invention also provides methods for inhibiting microglial activation by administering the compounds of the invention. | 08-26-2010 |
| 20100179327 | Synthesis of Methylphenidate and Analogs Thereof - A synthetic process for the preparation of amino acid esters such as methylphenidate and analogs thereof is disclosed. The process involves reacting an amino acid such as α-phenyl-α-(2-piperidinyl)acetic acid or an analog thereof with an alcohol such as methanol in the presence of an acid and a water sequestrant such as trimethyl orthoacetate. In some embodiments, the water sequestrant is added to the reaction mixture after an initial period of esterification and then the reaction is allowed to continue. The α-phenyl-α-(2-piperidinyl)acetic acid methyl ester or analog thereof is then isolated from the reaction mixture. In one variation of the process, the supernatant liquid may be recycled in subsequent runs to increase yield and product purity. | 07-15-2010 |
| 20100166864 | MATRIX-BASED PULSE RELEASE PHARMACEUTICAL FORMULATION - The present invention relates to an oral pulse release pharmaceutical composition, which comprises a polymer matrix core, wherein at least one pharmaceutically active ingredient is distributed within the core and on the outer surface of the core. Amphetamine salts, among a number of other pharmaceutically active ingredients, can be formulated as a pharmaceutical composition described herein. The present invention also provides a method for preparing an immediate release component on a solid pharmaceutical formulation. | 07-01-2010 |
| 20100137598 | Process for Preparing Hydrocodone Using a Super Acid - The present disclosure generally relates to a process for converting a fused, tricyclic compound to a fused, tetracyclic compound that includes a furan ring therein. More particularly, the present disclosure related to a process for preparing a hydrocodone compound, or a compound structurally related thereto, and in particular (+)-hydrocodone, by subjecting a structurally corresponding sinomenine starting compound to a super acid-assisted furan ring closure reaction. | 06-03-2010 |
| 20100113831 | Highly Pure Crystalline Benzphetamine Hydrochloride and Processes for Preparing - A highly pure crystalline form of benzphetamine hydrochloride and methods for the purification and crystallization of benzphetamine hydrochloride in high yield are disclosed. | 05-06-2010 |
| 20100113788 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates - The present invention is directed to the preparation of 6-keto morphinans. | 05-06-2010 |
| 20100113756 | LUMINESCENT METAL COMPLEXES FOR MONITORING RENAL FUNCTION - Some embodiments of the present invention may be said to be directed to metal complexes of Formula I wherein at least one of X | 05-06-2010 |
| 20100087647 | Processes for the production of buprenorphine with reduced impurity formation - The present invention provides process for the production of opiate alkaloids. In particular, the present invention provides processes for the production of buprenorphine or a derivative of buprenorphine that minimizes the formation of impurities. | 04-08-2010 |
| 20100081821 | Berberine compounds and processes for the preparation of berberine compounds - The invention is directed to berberine compounds and processes for the preparation of berberine compounds through an intramolecular Bischler-Napieralski cyclization. | 04-01-2010 |
| 20100081820 | Processes for the alkylation of norbuprenorphine with reduced impurity formation - The invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for the formation of buprenorphine and derivatives of buprenorphine that minimizes the formation of impurities. | 04-01-2010 |
| 20100081819 | Processes for the synthesis of tertiary amines - The invention provides processes for the preparation of morphinans having a tertiary amine. In particular, the present invention provides processes for the formation of tertiary amine alkaloids by direct N-alkylation of secondary amine alkaloids, the processes co-mediated by an alkylating agent and a protic solvent or a mixture of a protic solvent and an aprotic solvent. | 04-01-2010 |
| 20100081818 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates - The present invention is directed to the preparation of 6-hydroxy morphinans having formula (II) or N-alkylated 6-hydroxy morphinans having formula (III). | 04-01-2010 |
| 20100081817 | Processes for the selective amination of ketomorphinans - The present invention is generally directed to a process for the preparation of a ketomorphinan comprising maintaining a ketone group as unprotected and performing reductive amination using a hydrogen source and a catalyst. | 04-01-2010 |
| 20100081816 | Processes for synthesis of opiate alkaloid derivatives - The present invention provides processes for the synthesis of opiate alkaloids. In particular, the opiate alkaloids produced by the process of the invention are typically intermediate compounds that may be utilized to produce a variety of biologically active alkaloids including buprenorphine and diprenorphine. | 04-01-2010 |
| 20100081815 | Recycling process for increasing the yield of opiate alkaloid derivatives - The present invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for increasing the yield of opiate alkaloids by introducing at least one recycling step. | 04-01-2010 |
| 20100081814 | Processes for increasing the yield of opiate alkaloid derivatives - The present invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for recycling impurities into useful intermediates during the synthesis of opiate alkaloids. | 04-01-2010 |
| 20100081813 | Processes for the synthesis of opiates alkaloids with reduced impurity formation - The invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for the formation of opiate alkaloids that minimizes the formation of impurities. | 04-01-2010 |
| 20100076198 | Crystalline forms of Fentanyl Alkaloid - The present invention provides crystalline forms of fentanyl alkaloid and methods for preparing crystalline forms of fentanyl alkaloid. | 03-25-2010 |
| 20100076007 | Polymorphs of 6-Beta-Naltrexol - The present invention provides polymorphs of 6-beta-naltrexol and process for their preparation. In particular, the present invention provides crystalline forms of the free base of 6-beta-naltrexol and processes for their preparation. The present invention also provides crystalline and amorphous forms of the hydrochloride salt of 6-beta-naltrexol and processes for their preparation. | 03-25-2010 |
| 20100069639 | Processes for the Synthesis of Five and Six Membered Heterocyclic Rings - The present invention provides processes for the synthesis of five and six membered rings. In particular, the present invention provides processes for the synthesis of five and six membered rings in alkaloids. | 03-18-2010 |
| 20100056909 | Methods for Controlling Medical Fluid Injections - The present invention is directed to control of medical fluid injection systems. For instance, in some embodiments, an injection protocol may be initiated, and an actual flow rate of the medical fluid utilized in the injection protocol may be adjusted based, at least in part, on an inherent system elasticity of the injection system. | 03-04-2010 |
| 20100056789 | Substituted Berbines and Processes for their Synthesis - The present invention provides processes for the synthesis of substituted berbine compounds. Also provided are intermediates used in the synthesis of substituted berbine compounds. | 03-04-2010 |
| 20100056574 | Crystalline Forms of Sufentanil - The present invention provides crystalline forms of sufentanil citrate and methods for preparing crystalline forms of sufentanil citrate. | 03-04-2010 |
| 20100055179 | Composition of and Method for Preparing Orally Disintegrating Tablets Containing a High Dose of Pharmaceutically Active Ingredients - The present invention is directed to improved compositions and methods for preparing orally disintegrating tablets (ODTs). In one aspect of the present invention, the ODT further contains at least one active pharmaceutical ingredient (API). In another aspect of the present invention, the ODT contains a high load of at least one API. Specifically, the ODTs described in this invention containing a high load of API can accommodate up to about 70% w/w of active pharmaceutical ingredient in a unit dosage, while exhibiting the desirable attributes of fast disintegration time, acceptable hardness and friability for push through blister and bottle packages, and acceptable mouth feel. | 03-04-2010 |
| 20100051135 | CONTRAST CONTAINER HOLDER AND METHOD TO FILL SYRINGES - The filling of a syringe can be performed at a faster rate using a filling sequence which expels air from the fill tube before filling the syringe. A similar method is used when changing contrast containers during a filling sequence to ensure that all the air is expelled from the fill tube before filling resumes with the new contrast container. Additionally, by including a contrast container holder that is affixed to an injector head and holds the container near the syringe tip, the filling sequence can be accomplished without requiring the operator to hold the contrast container during the sequence. | 03-04-2010 |
| 20100041827 | MULTICOMPONENT ASSEMBLIES HAVING ENHANCED BINDING PROPERTIES FOR DIAGNOSIS AND THERAPY - An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule. | 02-18-2010 |
| 20100041826 | MULTICOMPONENT ASSEMBLIES HAVING ENHANCED BINDING PROPERTIES FOR DIAGNOSIS AND THERAPY - An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule. | 02-18-2010 |
| 20100035910 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts - An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives. | 02-11-2010 |
| 20100030153 | Injector Having Low Input Power - A powered injector that stores energy at a low rate when not in use and delivers energy at a high rate during injection. Energy may be stored in a highly responsive energy storage device, such as a capacitor, for rapid delivery of power to the injector motor. In certain embodiments, wires connecting the powered injector to a power supply may be relatively small and inexpensive because the current and voltage loads placed on the wires are relatively low. | 02-04-2010 |
| 20100022449 | RECEPTOR-AVID EXOGENOUS OPTICAL CONTRAST AND THERAPEUTIC AGENTS - Cyanine and indocyanine dye compounds and bioconjugates are disclosed. The present invention includes several cyanine and indocyanine dyes, including bioconjugates of the same, with a variety of bis- and tetrakis (carboxylic acid) homologues. The compounds of the invention may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive agents. The small size of compounds of the invention allows favorable delivery to tumor cells as compared to larger molecular weight imaging agents. Further, use of a biocompatible organic solvent such as dimethylsulfoxide may be said to assist in maintaining the fluorescence of compounds of the invention. The compounds and bioconjugates herein disclosed are useful in a variety of medical applications including, but not limited to, diagnostic imaging and therapy, endoscopic applications for the detection of tumors and other abnormalities, localized therapy, photoacoustic tumor imaging, detection and therapy, and sonofluorescence tumor imaging, detection and therapy. | 01-28-2010 |
| 20100021382 | Pyrazine Derivatives and Uses Thereof - Disclosed herein are pyrazine derivatives and methods of using the same. | 01-28-2010 |
| 20100010223 | Pyrazine derivatives, Methods of use, and methods for preparing same - The present invention relates to methods for producing N,N′-alkylated diaminopyrazines. | 01-14-2010 |
| 20090324497 | Tc and Re Labeled Radioactive Glycosylated Octreotide Derivatives - Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or prosthetic group to provide a complexation of a radioisotope binding or holding the radioisotope. The sst- or SSTR-receptor binding peptidic ligands may also contain one or more multifunctional linker units optionally coupling the peptide, and/or the sugar moiety and/or the chelator and/or the prosthetic group. Upon administering the ligand to a mammal through the blood system the ligand provides improved availability, clearance kinetics, sst-receptor targeting and internalization over the non-carbohydrated ligands. | 12-31-2009 |
| 20090312552 | Process for the Preparation of 6-Beta Hydroxy Morphinan Compounds - The invention provides processes for the conversion of a 6-keto morphinan to a 6-hydroxy morphinan. In particular, the invention provides a stereoselective process for the conversion of a 6-keto morphinan to a 6-beta-hydroxy morphinan. | 12-17-2009 |
| 20090302499 | METHOD FOR MAKING A RADIOPHARMACEUTICAL PIG - A pharmaceutical pig is used to transport a syringe containing a liquid radiopharmaceutical from a radiopharmacy to a medical facility for administration to a patient. The pharmaceutical pig includes an elongate polymer cap that is removably attached to an elongate polymer base. The elongate polymer cap includes a cap shell that completely encloses a cap shielding element and the elongate polymer base includes a base shell that completely encloses a base shielding element. Preferably the polymer utilized for the cap shell and the base shell is polycarbonate resin, e.g., LEXAN®. An inner liner is not utilized and the cap shielding element and the base shielding element, which are preferably, but not necessarily, made of lead, are completely sealed and unexposed. | 12-10-2009 |
| 20090299177 | Risk Stratification of Patients with Chronic Myocardial Infarction - The present invention is directed to novel radiopharmaceuticals, which can be used to image myocardium. In addition, the present invention is directed to methods for risk stratification of patients who have suffered at least one myocardial infarction. | 12-03-2009 |
| 20090299069 | Processes and Compounds for the Preparation of Normorphinans - The invention generally provides processes and intermediate compounds useful for the production of normorphinans and derivatives of normorphinans. | 12-03-2009 |
| 20090280057 | Combination of Intercalating Organometallic Complexes and Tumor Seeking Biomolecules for DNA Cleavage and Radiotherapy - The invention relates to molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is preferably a radioactive metal, to the use of these molecules and to therapeutic and diagnostic compositions containing them. | 11-12-2009 |
| 20090278062 | METHODS OF USING RADIOPHARMACEUTICAL PIGS - A pharmaceutical pig is used to transport a syringe containing a liquid radiopharmaceutical from a radiopharmacy to a medical facility for administration to a patient. The pharmaceutical pig includes an elongate polymer cap that is removably attached to an elongate polymer base. The elongate polymer cap includes a cap shell that completely encloses a cap shielding element and the elongate polymer base includes a base shell that completely encloses a base shielding element. Preferably the polymer utilized for the cap shell and the base shell is polycarbonate resin, e.g., LEXAN®. An inner liner is not utilized and the cap shielding element and the base shielding element, which are preferably, but not necessarily, made of lead, are completely sealed and unexposed. | 11-12-2009 |
| 20090263327 | MINIMALLY INVASIVE PHYSIOLOGICAL FUNCTION MONITORING AGENTS - Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo. | 10-22-2009 |
| 20090258843 | Compositions Containing Antiviral Compounds and Methods of Using the Same - The present invention is directed to compositions and methods for the treatment of various diseases, pathological disorders, and medical conditions such as viral infections and cancer. The compositions include (A) an antiviral compound or a pharmaceutically acceptable salt thereof; and (B) an agent selected from the group consisting of a substituted or unsubstituted imidazole or a pharmaceutically acceptable salt thereof; a non-steroidal anti-inflammatory agent or a pharmaceutically acceptable salt thereof; an amino acid or a pharmaceutically acceptable salt thereof; a carboxylic acid or a pharmaceutically acceptable salt thereof; a sulfonic acid or a pharmaceutically acceptable salt thereof; and a combination thereof. | 10-15-2009 |
| 20090252674 | Tripodal Ligands with the Coordinating Motifs K2 -BH2 or K3 -BH3 Relevant for Biomedical Applications of Organometallic Complexes - The present invention relates to a compound for use as a chelator in the radioactive labeling of biomolecules with metal tricarbonyl complexes, which compound has the general Formula (I) wherein M is a monovalent cation, such as Li, Na, K, Tl, Rb, Cs or an alkyl ammonium; R1 is H, alkyl, aryl or a biomolecule; R2 is H or a pendant arm, said pendant arm optionally comprises a biomolecule, with the proviso that when R1 is H, R2 is not H or COOH, and when R1 is alkyl or aryl, R2 is not H. | 10-08-2009 |
| 20090247761 | Preparation of 3,4-Dihydroisoquinolines in the Synthesis of Morphinans - The present invention is directed to processes for the synthesis of morphinans. In particular, a process for coupling a carboxylic acid compound with an amine compound to form an amide product that can then be isolated or the crude amide product can be cyclized to form a 3,4-dihydroisoquinoline. In one embodiment, the carboxylic acid contains a phenol moiety protected with a labile protecting group. The protected phenol reduces reaction times, simplifies work-up of the product, and reduces the amount of cyclizing agent, POCl | 10-01-2009 |
| 20090247760 | Preparation of Amides from an Acid and Amine for Intermediates in the Synthesis of Morphinans - The present invention is directed to processes for the synthesis of morphinans. In particular, a process for coupling a carboxylic acid compound with an amine compound to form an amide product that can then be isolated or the crude amide product can be cyclized to form a 3,4-dihydroisoquinoline. In one embodiment, the carboxylic acid contains a phenol moiety protected with a labile protecting group. The protected phenol reduces reaction times, simplifies work-up of the product, and reduces the amount of cyclizing agent, POCl | 10-01-2009 |
| 20090247756 | Process for the Preparation of Hexahydroisoquinolines from 1,2,3,4-Tetrahydroisoquinolines - The present invention is directed to processes for the synthesis of morphinans. In particular, a process for the asymmetric reduction of an imine moiety in a 3,4-dihydroisoquinoline to produce a tetrahydroisoquinoline, followed by a Birch reduction to produce a hexahydroisoquinoline. In various embodiments, the 3,4-dihydroisoquinoline contains a phenol moiety protected with a labile protecting group. In other embodiments, the imine reduction reaction mixture contains silver tetrafluoroborate. | 10-01-2009 |
| 20090232896 | Use of Magnesium Stearate Dihydrate for Lubrication of Solid Pharmaceutical Compositions - The invention provides lubricant compositions comprising magnesium stearate dihydrate. The lubricant compositions may be used to lubricate a variety of bioactive formulations including pharmaceutical compositions. | 09-17-2009 |
| 20090221825 | Process for the Preparation of 3-Hydroxymorphinan Derivatives - Processes are described for the synthesis of 3-hydroxymorphinan derivatives by hydrolysis of side products from the O-demethylation of 3-methoxymorphinan derivatives. | 09-03-2009 |
| 20090221791 | Composition and Method for the Release of Protected Peptides from a Resin - The present invention provides a composition and a method for cleaving a peptide from a solid support resin. Hydrochloric acid in an organic water miscible solvent is used to cleave the peptide-resin attachment. Optionally, trifluoroethanol or hexafluoroisopropanol may be added to the cleavage composition to improve results. When using the present cleavage composition, an evaporation or other step to remove carboxylic byproducts is not necessary following the cleavage reaction. After the resin is filtered out of the cleavage mixture, the peptide may be immediately precipitated with water. | 09-03-2009 |
| 20090131587 | Solid Support for Fmoc-Solid Phase Synthesis of Peptides - The present invention provides compositions and processes for the solid phase synthesis of polypeptides. In particular, the present invention provides solid supports and processes for preparing solid supports for the synthesis of polypeptides. | 05-21-2009 |
| 20090124833 | Process for the Purification of Benzphetamine Hydrochloride - The present invention relates to the economical and separation of benzphetamine hydrochloride and methamphetamine by liquid extraction. An extraction process employing a suitable organic solvent and water at a pH in the range of from about 6 to about 8 provides excellent removal of the methamphetamine by dissolution in the water phase while the benzphetamine dissolves in the organic phase. Simple separation of the two phases results in separation of the two amines. | 05-14-2009 |
| 20090069747 | Power Injector with Movable Joint-Integrated Signal Transmission Connector - A power injector that incorporates at least one signal transmission connector in a movable joint (e.g., between a powerhead and a support or stand; between at least one adjacent pair of support sections of a support for the powerhead) is disclosed. Such a signal transmission connector may be in the form of a slip ring module, but in any case is part of the signal transmission link to the powerhead. At least that portion of a signal transmission conduit that is adjacent to the powerhead may be disposed within the interior of the corresponding portion of the support or stand, thereby reducing the potential that an individual will grab onto the signal transmission conduit when attempting to move at least part of the power injector, to change the position of the powerhead, or both. | 03-12-2009 |
| 20090010851 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function - The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X | 01-08-2009 |
| 20080306443 | Medical Fluid Injector Having Wireless Pressure Monitoring Feature - The present invention relates to medical fluid injectors. An exemplary injector may include a drive ram that is adapted to interface with a plunger of a syringe. The drive ram may be equipped with an RF enabled pressure sensor that is configured to measure pressure exerted on the syringe plunger by the drive ram. In addition, the injector may include an RF circuit in RF communication with the pressure sensor of the drive ram. In some embodiments, the injector may include a controller in electrical communication with the RF circuit. The controller may be configured to adjust movement of the drive ram to alter the pressure exerted on the syringe plunger by the drive ram (i.e., the pressure measured by the pressure sensor). | 12-11-2008 |
| 20080299038 | Luminescent Metal Complexes for Monitoring Renal Function - Some embodiments of the present invention may be said to be directed to metal complexes of Formula I, wherein at least one of X | 12-04-2008 |
| 20080287757 | Sensor with signature of data relating to sensor - A sensor has codes useful for a monitor which can be authenticated as accurate. The sensor produces a signal corresponding to a measured physiological characteristic and provides codes which can be assured of being accurate and authentic when used by a monitor. A memory associated with the sensor stores both data relating to the sensor and a digital signature. The digital signature authenticates the quality of the code by ensuring it was generated by an entity having predetermined quality controls, and ensure the code is accurate. | 11-20-2008 |
| 20080211674 | SYSTEMS AND METHODS FOR MANAGING INFORMATION RELATING TO MEDICAL FLUIDS AND CONTAINERS THEREFOR - The present invention relates to management of information relating to medical fluids, containers therefor, and medical fluid administration devices for administering such medical fluids to patients. Data tags (e.g., RFID tags) are generally associated with containers of the invention and may be electromagnetically read from and/or written to using an electromagnetic device, for example, that may be associated with a medical fluid administration device of the invention. | 09-04-2008 |
| 20080208042 | SYSTEMS AND METHODS FOR MANAGING INFORMATION RELATING TO MEDICAL FLUIDS AND CONTAINERS THEREFOR - The present invention relates to management of information relating to medical fluids, containers therefor, and medical fluid administration devices for administering such medical fluids to patients. Data tags (e.g., RFID tags) are generally associated with containers of the invention and may be electromagnetically read from and/or written to using an electromagnetic device, for example, that may be associated with a medical fluid administration device of the invention. | 08-28-2008 |
